Holen Sie sich die Stockscreener-App
15.63
3.10%
0.47
Schlusskurs vom Vortag:
$15.16
Offen:
$15.52
24-Stunden-Volumen:
168.46K
Relative Volume:
0.92
Marktkapitalisierung:
$532.89M
Einnahmen:
$99.53M
Nettoeinkommen (Verlust:
$-21.57M
KGV:
-24.09
EPS:
-0.6488
Netto-Cashflow:
$-9.84M
1W Leistung:
-1.33%
1M Leistung:
-2.25%
6M Leistung:
-0.70%
1J Leistung:
+47.45%
1-Tages-Spanne:
$15.14
$15.65
1-Wochen-Bereich:
$14.88
$15.97
52-Wochen-Spanne:
$7.5625
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
15.63 | 532.89M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuropace Inc (NPCE) Institutional Confidence - TradingKey
Neuropace Inc (NPCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuropace Inc (NPCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuropace Inc (NPCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade - MSN
(NPCE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroPace (NPCE) down 0.6% since last earnings report: Can it rebound? - MSN
Here's why you should add NeuroPace stock to your portfolio now - MSN
NPCE Explains How NeuroPace's RNS System Makes Money - MSN
NeuroPace Stock Draws Focus As RNS Adoption Expands - Kalkine Media
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Yahoo Finance
NeuroPace, Inc. Files Form 8-K Reporting 2026 Annual Meeting Results and Company Information - Minichart
NeuroPace shareholders elect directors and ratify auditor at annual meeting By Investing.com - Investing.com South Africa
NeuroPace shareholders elect directors and ratify auditor at annual meeting - Investing.com
NeuroPace Shareholders Approve Directors and Auditor at Meeting - TipRanks
NeuroPace (NASDAQ: NPCE) investors back board slate and PwC at 2026 meeting - Stock Titan
(NPCE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NeuroPace (NPCE) director receives new stock grant and options - Stock Titan
NeuroPace (NPCE) director Fischer receives stock and option awards - Stock Titan
NeuroPace (NPCE) director Uri Geiger receives new share and option grants - Stock Titan
NeuroPace (NPCE) director receives stock grant and 5,368-share option award - Stock Titan
NeuroPace (NPCE) director receives new stock and option grants as compensation - Stock Titan
NeuroPace (NASDAQ: NPCE) director receives new stock and option grants - Stock Titan
NeuroPace (NPCE) CEO Becker has RSU tax withholding of 1,255 shares - Stock Titan
How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target - Yahoo Finance
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy - Zacks Investment Research
NeuroPace Shares Little Changed After FDA Greenlights AI Device - Bez Kabli
NeuroPace Wins FDA Nod for ECoG Assistant for Epilepsy Care - Medical Product Outsourcing
NPCE Q1 2026 Earnings: Narrower-than-Expected Loss Drives Better-Than-Feared ResultsEarnings Acceleration Picks - thelegaladvocate.com
NeuroPace receives FDA approval for AI-driven ECoG Assistant - Investing.com UK
NeuroPace receives FDA approval for AI-driven ECoG Assistant By Investing.com - Investing.com Nigeria
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery Meeting - Investing News Network
NPCENeuropace Inc. stock news, filings & ratings - Quantisnow
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting - Business Wire
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care - Business Wire
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):